This site is intended only for healthcare professionals in UAE, Kuwait, Qatar, Bahrain, Oman.

Search

Menu

Close

Sign In or Register

Log OutOur Medicines Therapy AreasExplore ContentExplore Content

Events

Downloadable materialsVideosLet's ConnectLet's ConnectContact usPfizer medical information

Menu

Close

AboutAboutCOVID OverviewIndicationsMechanism of ActionEfficacyDosingSafetyPatient ProfilesFAQsImportant Safety InformationResourcesResourcesEventsMaterialsVideos

This information is only valid for healthcare professionals in Bahrain, Kuwait, Qatar & UAE.
PaxlovidTM (nirmatrelvir and ritonavir) is available, marketed and has a Health Registry only in Bahrain, Kuwait, Qatar & UAE.

Information on how to access PaxlovidTM (nirmatrelvir and ritonavir) prescribing information and adverse event reporting can be found at the bottom of the page.

DosingPAXLOVID™ is taken orally, at home, twice daily for 5 days.1

Treatment should begin immediately following a positive COVID-19 test and within ≤5 days from symptom onset. PAXLOVID™ dosing instructions1:
  • PAXLOVID™ can be taken with or without food
  • The tablets should be swallowed whole and not chewed, broken or crushed
  • If a dose is missed and it is within 8 hours of the normal dosing schedule, the patient should take the dose immediately and resume their normal schedule
  • If a dose is missed and it is more than 8 hours after the normal dosing schedule, the patient should not take the missed dose and should instead take their next dose at the regularly scheduled time.
PAXLOVID™Dosing Instructions Understanding Dose Adjustments
Indication
 Learn More Loading
Efficacy
 Learn More Loading
COVID-19 Overview Learn  MoreLoading
COVID-19, coronavirus disease 2019; eGFR, estimated glomerular filtration rate.


Reference: 1. PaxlovidTM (nirmatrelvir and ritonavir) Local Product Document. Revision Date: October 2022 for Kuwait, January 2024 for Bahrain, Qatar & UAE.

Prescribing Information:
 

Bahrain Prescribing Information
Kuwait Prescribing Information
Qatar Prescribing Information
UAE Prescribing Information
PP-C1D-BHR-0061

This information is valid only for healthcare professionals in Bahrain, Kuwait, Qatar & UAE.

Report Adverse Events 

If you'd like to report an adverse event related to a Pfizer Product from Gulf (UAE, Bahrain, Qatar, Oman and Kuwait), please send an email with the adverse event details to: [email protected]

Pfizerpro accountPfizerPro Account

Access Pfizer materials, resources and receive communications from Pfizer about our products with a Pfizerpro account.

Sign In or Register

AccountSign Out

Copyright © 2025 Pfizer Gulf FZ LLC. All rights reserved.

 

i- The product information provided in this site is intended only for Healthcare Professionals of UAE, Kuwait, Qatar, Bahrain, Oman.

 

ii- The information contained on this website is offered for educational purposes only and does not represent medical advice, diagnosis, treatment or a professional recommendation. Pfizer will not be responsible for the use or interpretation of the information by the user of the website.

 

iii- The products discussed herein may have a different product labeling than authorized in your country and may not be available in some territories.

PP-UNP-BHR-0411

You are now leaving Pfizer

You are now leaving Pfizerpro and will be directed to our provider to complete your registration. Any personal information that you may find pre-populated from your Pfizerpro profile, or you may provide, will be governed by our Privacy Policy. Your data will not be used for any other purpose.

 

You are now leaving PfizerPro
​
You are leaving the Pfizer Portal - would you like to continue?
 

​​​​​​​